A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis
A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis
Not yet recruiting · NCT07335562 · Registry updated 2026-09-18Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis | Skin and Connective Tissue Diseases, connective tissue disorder, skin disorder, systemic sclerosis | Not yet recruiting | Phase 3 | 2026-09-18 | NCT07335562 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Celgene Corporation | 20 |
| Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | 17 |
4 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Cleveland Clinic | Cleveland | United States | 558 |
| Colorado Blood Cancer Institute | Denver | United States | 178 |
| Emory University School of Medicine | Atlanta | United States | 47 |
| University of Colorado Anschutz Medical Campus | Aurora | United States | 142 |